PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCalfactant
Calfactant
Infasurf (calfactant) is an unknown pharmaceutical. Calfactant was first approved as Infasurf on 1998-07-01. It is used to treat newborn respiratory distress syndrome in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Infasurf
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Calfactant
Tradename
Proper name
Company
Number
Date
Products
InfasurfcalfactantONY BiotechN-20521 RX1998-07-01
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
infasurfBiologic Licensing Application2024-10-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
newborn respiratory distress syndrome—D012127P22
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory distress syndromeD012128EFO_1000637J80—141511
Newborn respiratory distress syndromeD012127—P22—141511
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bronchopulmonary dysplasiaD001997—P27.8122—15
SyndromeD013577———11—13
Acute lung injuryD055371EFO_0004610——12——2
HyperplasiaD006965EFO_0000536———1——1
Lung injuryD055370—S27.30—11——1
Premature birthD047928EFO_0003917O60——1——1
Lung transplantationD016040———11——1
Primary graft dysfunctionD055031———11——1
Perinatal deathD066087HP_0003811———1——1
Intratracheal intubationD007442————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung diseasesD008171HP_0002088J98.4—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BronchiolitisD001988HP_0011950—1————1
Connective tissue diseasesD003240EFO_1001986M351————1
Skin and connective tissue diseasesD017437——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FibrosisD005355——————11
Cystic fibrosisD003550EFO_0000390E84————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCalfactant
INN—
Description
Calfactant, also known as Infasurf, is an intratracheal suspension derived from the natural surfactant in calf lungs. It is used in premature infants with lung surfactant deficiency that causes infant respiratory distress syndrome (IRDS).
Classification
Small molecule
Drug classpulmonary surfactants; tachykinin (neurokinin) receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID183325-78-2
RxCUI232539
ChEMBL IDCHEMBL1201447
ChEBI ID—
PubChem CID—
DrugBankDB06415
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 526 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
103 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use